The global human embryonic stem cells market is expected to grow at a CAGR of 12.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing demand for stem cells in research and clinical trials, as well as their potential use in regenerative medicine.
The global human embryonic stem cells market can be segmented on the basis of type into totipotent stem cells, pluripotent stem cells, and unipotent stem cells. The pluripotent cell segment accounted for the largest share of this market in 2018 owing to its ability to differentiate into any type of cell found in an organism. Unipotent cell segment is expected to grow at a higher CAGR during the forecast period due to its ability for differentiation into only one type of cell found in an organism such as erythrocytes or neurons.
On the basis of application, this market can be divided into research and clinical trials segments. Research applications are expected to account for a larger share due to their extensive use by researchers across various fields such as drug discovery and development, regenerative medicine, tissue engineering etc, whereas clinical trials are projected have higher growth rate during the forecast period owing mainly due increased demand from pharmaceutical companies for conducting clinical trials with HESCs which will lead them towards investing more on these types of therapies than other types like gene therapy or immunotherapy treatments which are not yet approved by regulatory authorities globally.
Some Of The Growth Factors Of This Market:
- HESC are pluripotent cells that can differentiate into any cell type in the body, which makes them a promising source of cells for regenerative medicine.
- HESC have been used to treat Parkinson's disease, spinal cord injury, and diabetes mellitus type 1.
- The use of HESC is controversial because they are derived from human embryos and their use may lead to the destruction of human embryos.
- The United States has banned federal funding for research on new lines of embryonic stem cells created after August 9, 2001 (Dickey-Wicker Amendment).
- There is a potential risk that HESC could form tumors or other abnormal tissue if transplanted into humans or animals.
Industry Growth Insights published a new data on “Human Embryonic Stem Cells (HESC) Market”. The research report is titled “Human Embryonic Stem Cells (HESC) Market research by Types (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), By Applications (Research, Clinical Trials, Others), By Players/Companies ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Embryonic Stem Cells (HESC) Market Research Report
By Type
Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells
By Application
Research, Clinical Trials, Others
By Companies
ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Human Embryonic Stem Cells (HESC) Market Report Segments:
The global Human Embryonic Stem Cells (HESC) market is segmented on the basis of:
Types
Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Clinical Trials, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ESI BIO
- Thermo Fisher
- BioTime
- MilliporeSigma
- BD Biosciences
- Astellas Institute of Regenerative Medicine
- Asterias Biotherapeutics
- Cell Cure Neurosciences
- PerkinElmer
- Takara Bio
- Cellular Dynamics International
- Reliance Life Sciences
- Research & Diagnostics Systems
- SABiosciences
- STEMCELL Technologies
- Stemina Biomarker Discovery
- Takara Bio
- TATAA Biocenter
- UK Stem Cell Bank
- ViaCyte
- Vitrolife
 Market Overview.svg)
Highlights of The Human Embryonic Stem Cells (HESC) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Totipotent Stem Cells
- Pluripotent Stem Cells
- Unipotent Stem Cells
- By Application:
- Research
- Clinical Trials
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Embryonic Stem Cells (HESC) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human embryonic stem cells are a type of cell that can be used to create new tissue. These cells come from the innermost layer of the early embryo, and can be used to treat diseases or injuries in adults.
Some of the key players operating in the human embryonic stem cells (hesc) market are ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolife.
The human embryonic stem cells (hesc) market is expected to grow at a compound annual growth rate of 12.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Embryonic Stem Cells (HESC) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Embryonic Stem Cells (HESC) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Embryonic Stem Cells (HESC) Market - Supply Chain
4.5. Global Human Embryonic Stem Cells (HESC) Market Forecast
4.5.1. Human Embryonic Stem Cells (HESC) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Embryonic Stem Cells (HESC) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Embryonic Stem Cells (HESC) Market Absolute $ Opportunity
5. Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
5.3.1. Totipotent Stem Cells
5.3.2. Pluripotent Stem Cells
5.3.3. Unipotent Stem Cells
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
6.3.1. Research
6.3.2. Clinical Trials
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Embryonic Stem Cells (HESC) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Embryonic Stem Cells (HESC) Demand Share Forecast, 2019-2026
9. North America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
9.4.1. Research
9.4.2. Clinical Trials
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
9.7.1. Totipotent Stem Cells
9.7.2. Pluripotent Stem Cells
9.7.3. Unipotent Stem Cells
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Embryonic Stem Cells (HESC) Demand Share Forecast, 2019-2026
10. Latin America Human Embryonic Stem Cells (HESC) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
10.4.1. Research
10.4.2. Clinical Trials
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
10.7.1. Totipotent Stem Cells
10.7.2. Pluripotent Stem Cells
10.7.3. Unipotent Stem Cells
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Embryonic Stem Cells (HESC) Demand Share Forecast, 2019-2026
11. Europe Human Embryonic Stem Cells (HESC) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
11.4.1. Research
11.4.2. Clinical Trials
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
11.7.1. Totipotent Stem Cells
11.7.2. Pluripotent Stem Cells
11.7.3. Unipotent Stem Cells
11.8. Basis Point Shar (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Embryonic Stem Cells (HESC) Demand Share, 2019-2026
12. Asia Pacific Human Embryonic Stem Cells (HESC) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
12.4.1. Research
12.4.2. Clinical Trials
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
12.7.1. Totipotent Stem Cells
12.7.2. Pluripotent Stem Cells
12.7.3. Unipotent Stem Cells
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Embryonic Stem Cells (HESC) Demand Share, 2019-2026
13. Middle East & Africa Human Embryonic Stem Cells (HESC) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Application
13.4.1. Research
13.4.2. Clinical Trials
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Embryonic Stem Cells (HESC) Market Size and Volume Forecast by Type
13.7.1. Totipotent Stem Cells
13.7.2. Pluripotent Stem Cells
13.7.3. Unipotent Stem Cells
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Embryonic Stem Cells (HESC) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Embryonic Stem Cells (HESC) Market: Market Share Analysis
14.2. Human Embryonic Stem Cells (HESC) Distributors and Customers
14.3. Human Embryonic Stem Cells (HESC) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ESI BIO
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Thermo Fisher
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. BioTime
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. MilliporeSigma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BD Biosciences
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Institute of Regenerative Medicine
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Asterias Biotherapeutics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cell Cure Neurosciences
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. PerkinElmer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Takara Bio
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cellular Dynamics International
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Reliance Life Sciences
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Research & Diagnostics Systems
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. SABiosciences
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. STEMCELL Technologies
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Stemina Biomarker Discovery
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Takara Bio
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. TATAA Biocenter
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. UK Stem Cell Bank
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. ViaCyte
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
